Studies on the characteristic and activity of low-molecular fragments from zymosan

Investigation of the structural and immunomodulatory properties of alkali-soluble β-glucans from Pleurotus eryngii fruiting bodies

Fungal β-glucans have received a lot of interest due to their proinflammatory activity towards cells of the innate immune system. Although commonly described as (1➔3)-β-glucans with varying degree of (1➔6)-branching, the fungal β-glucans constitute a diverse polysaccharide class. In this study, the alkali-soluble β-glucans from the edible mushroom Pleurotus eryngii were extracted and characterized by GC, GC-MS and 2D NMR analyses. The extracts contain several structurally different polysaccharides, including a (1➔3)-β-d-glucan with single glucose units attached at O-6, and a (1➔6)-β-d-glucan, possibly branched at O-3. The immunomodulatory activities of the P. eryngii extracts were assessed by investigating their ability to bind to the receptor dectin-1, and their ability to induce production of the proinflammatory cytokines TNF-α, IL-6 and IL-1β in LPS-differentiated THP-1 cells. Although the samples were able to bind to the dectin-1a receptor, they did not induce production of significant levels of cytokines in the THP-1 cells. Positive controls of yeast-derived (1➔3)-β-d-glucans with branches at O-6 induced cytokine production in the cells. Thus, it appears that the P. eryngii β-glucans are unable to induce production of proinflammatory cytokines in LPS-differentiated THP-1 cells, despite being able to activate the human dectin-1a receptor.

Synthesis, Characterization, and Biological Activity of Aminated Zymosan

Zymosan (ZM), a naturally occurring insoluble macromolecule obtained from the cell wall of Saccharomyces cerevisiae, is used as a functional food (as dietary fiber), phagocytic stimulus, and immune potentiator. The present study aimed to increase its solubility and evaluate its immunological application. ZM was converted into soluble 6-amino-6-deoxy-β-(1-3)-glucan of a molecular weight of 296 kDa by reduction. Detailed structural characterization of aminated ZM was determined by Fourier transform infrared spectroscopy and two-dimensional NMR analysis (2D, COSY, TOCSY, ROSEY, NOSEY, and HSQC). Aminated ZM was biocompatible with Raw 264.7 macrophage cell lines up to a concentration of 100 μg/mL. Rhodamine tagging revealed that the aminated ZM microparticles were found localized within the nucleus of Raw 264.7 cells. Both native and aminated ZM showed a similar expression pattern of inflammatory genes in Raw 264.7.

Comparative study of bacterial translocation control with nitric oxide donors and COX2 inhibitor

OBJECTIVE AND DESIGN

To evaluate the beneficial effects of exogenous NO and an inhibitor of the COX2, and their action levels in a model of SIRS/bacterial translocation (BT) induced by Zymosan A(®).

MATERIAL AND METHODS

Ninety Wistar rats were submitted to different treatments, and after 12h and 24h they were anaesthetized in order to collect blood, mesenteric lymph nodes, and kidney for subsequent biochemical analyses and microbiological examinations.

TREATMENTS

A nitric oxide donor, Molsidomine(®), was compared with a COX2 inhibitor, Celecoxib(®).

METHODS

Zymosan A(®) was administered to Wistar rats. The animals were divided into 6 groups: one group for survival study, Group (1) No manipulation (BASAL); Group (2) vehicle of Zymosan A(®) given intraperitoneally (SHAM); Group I (control), with Zymosan A(®) (0.6g/kg) intraperitoneally; Group II (Molsidomine), with Molsidomine(®) (4mg/kg) through the penis dorsal vein, 30min prior to administration of the Zy(®) (0.6g/kg); Group III (Celecoxib), with Celecoxib(®) (400mg/kg) orally through a stomach tube, 6h prior to administration of the Zy (0.6g/kg).

DETERMINATIONS

The parameters survival, bacterial translocation, renal function, neutrophil accumulation, oxygen free radicals (OFR), detoxifying enzymes, and cytokines were measured at different times after Zymosan administration.

RESULTS

The model established induced a mortality rate of 100% and generated BT and systemic inflammatory response syndrome (SIRS) in all samples. It also significantly increased all variables, with p<.001 for MPO and all pro-inflammatory cytokines, and p<.01 for all OFR. Treatment with Molsidomine reduced mortality to 0%, decreased BT, MPO, pro-inflammatory cytokines and OFR (p<.001) significantly and increased IL-10 and IL-6 production. Moreover, the Celecoxib(®) showed a lower capacity for SIRS regulation.

CONCLUSIONS

The exogenous administration of NO prevented BT and controlled SIRS. Therefore these results suggest that Molsidomine could be used as a therapeutic strategy to protect against BT.